Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intratumoral IVX037 in Advanced or Metastatic Solid Tumours
NCT05427487Phase 1Recruiting
- Sponsor
- ImmVirX
- Start
- Feb 2023
- Primary completion
- Jun 2028
- Modality
- Oncolytic Viruses, RNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of IVX037 in colorectal cancer (CRC), gastric cancer (GC) and ovarian cancer (2 arms), sponsored by ImmVirX. Primary endpoints: Feasibility, safety, and tolerability of intratumoral IVX037 and Safety and efficacy of intratumoral IVX037 in combination with an intravenous immune checkpoint inhibitor. Started Feb 2023; status: recruiting.
02
Drugs
IVX037
03
Conditions
colorectal cancer (CRC)gastric cancer (GC)ovarian cancer
Beyond the preview
Go deeper on NCT05427487.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05427487.